Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer

To report the outcomes of patients treated with combined iodine-125 (I-125) brachytherapy and external beam radiotherapy (EBRT) for high-risk prostate cancer. Between 2003 and 2009, I-125 permanent prostate brachytherapy plus EBRT was performed for 206 patients with high-risk prostate cancer. High-r...

Full description

Saved in:
Bibliographic Details
Published in:Radiation oncology (London, England) England), 2014-01, Vol.9 (1), p.13-13, Article 13
Main Authors: Ohashi, Toshio, Yorozu, Atsunori, Saito, Shiro, Momma, Tetsuo, Nishiyama, Toru, Yamashita, Shoji, Shiraishi, Yutaka, Shigematsu, Naoyuki
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Androgen Antagonists - adverse effects
Androgen Antagonists - therapeutic use
Androgens
Biochemistry
Brachytherapy - adverse effects
Brachytherapy - methods
Cancer therapies
Combined Modality Therapy
Disease-Free Survival
Drug dosages
Failure analysis
Health aspects
Humans
Male
Medical prognosis
Middle Aged
Mortality
Prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Prostatic Neoplasms - radiotherapy
Radiation therapy
Radioisotope brachytherapy
Radiotherapy, Adjuvant
Radiotherapy, Conformal - adverse effects
Radiotherapy, Conformal - methods
Risk Factors
Seeds
Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To report the outcomes of patients treated with combined iodine-125 (I-125) brachytherapy and external beam radiotherapy (EBRT) for high-risk prostate cancer. Between 2003 and 2009, I-125 permanent prostate brachytherapy plus EBRT was performed for 206 patients with high-risk prostate cancer. High-risk patients had prostate-specific antigen ≥ 20 ng/mL, and/or Gleason score ≥ 8, and/or Stage ≥ T3. One hundred and one patients (49.0%) received neoadjuvant androgen deprivation therapy (ADT) but none were given adjuvant ADT. Biochemical failure-free survival (BFFS) was determined using the Phoenix definition. The 5-year actuarial BFFS rate was 84.8%. The 5-year cause-specific survival and overall survival rates were 98.7% and 97.6%, respectively. There were 8 deaths (3.9%), of which 2 were due to prostate cancer. On multivariate analysis, positive biopsy core rates and the number of high-risk factors were independent predictors of BFFS. The 5-year BFFS rates for patients in the positive biopsy core rate
ISSN:1748-717X
1748-717X
DOI:10.1186/1748-717x-9-13